# Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

> **NCT01290302** · PHASE1 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Myelofibrosis
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Luitpold Azacitidine
- **DRUG:** Vidaza®

## Key facts

- **NCT ID:** NCT01290302
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-22
- **Primary completion:** 2012-12
- **Final completion:** 2012-12-21
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290302, "Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01290302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*